Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D09EDA
|
|||
| Former ID |
DNCL003513
|
|||
| Drug Name |
PRM-151
|
|||
| Indication | Idiopathic pulmonary fibrosis [ICD-11: CB03.4; ICD-10: J84.1; ICD-9: 516.3] | Phase 2 | [1] | |
| Macular degeneration [ICD-11: 9B78.3; ICD-10: H35.3; ICD-9: 362.5] | Phase 2 | [2] | ||
| Myelofibrosis [ICD-11: 2A20.2; ICD-10: D47.4] | Phase 2 | [1], [3] | ||
| Polycythemia vera [ICD-11: 2A20.4; ICD-10: D45; ICD-9: 238.4] | Phase 2 | [3] | ||
| Thrombocythemia [ICD-11: 3B63; ICD-9: 289.9] | Phase 2 | [3] | ||
| Company |
Promedior
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Neuronal pentraxin-2 (NPTX2) | Target Info | Modulator | [2] |
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | PRM-151 (recombinant human serum amyloid P/pentraxin 2) for the treatment of fibrosis. Drug News Perspect. 2010 Jun;23(5):305-15. | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.